Safe vaccination of children with a virosomal adjuvanted influenza vaccine

A post-marketing study was conducted in 26 paediatric practices in Germany to collect safety information on the virosomal adjuvanted influenza vaccine Inflexal® V (in Germany marketed as Infectovac Flu®). Children aged 6 months to 6 years received one or two doses. Adverse events were documented by parents/legal guardians in a questionnaire for four days after vaccination. The rates of adverse events were low: 14% of vaccine exposures were associated with systemic and 25% with local adverse events. Most symptoms were mild to moderate and resolved within a few days. Nearly 100% of parents/legal guardians would agree to have their child vaccinated again with Inflexal® V. Vaccination with Inflexal® V was safe, well tolerated and highly accepted by parents/legal guardians.